Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. In our lead programs, we are developing multiple product candidates that target the insulin-like growth factor-1 receptor (IGF-1R) to treat patients who suffer from thyroid eye disease (TED), a debilitating auto-immune disease.
Learn more about Viridian and our programs in our corporate presentation.
Recent Press Releases
- Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
- Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
- Viridian Therapeutics to Present at Upcoming Investor Conferences